The full consensus on the role of dietary polyphenols as human‐health‐promoting compounds
remains elusive. The two‐way interaction between polyphenols and gut microbiota (GM) (…

Despite the high human interindividual variability in response to (poly)phenol consumption,
the cause-and-effect relationship between some dietary (poly)phenols (flavanols and olive …

Scope Gut microbiota dysbiosis, intestinal barrier failure, obesity, metabolic endotoxemia,
and pro‐inflammatory status promote cardiovascular risk. However, the modulation of the gut …

Scope The gut microbiota ellagitannin‐metabolizing phenotypes (ie, urolithin metabotypes [UMs])
are proposed as potential cardiovascular disease (CVD) risk biomarkers because the …

Urolithins, metabolites produced by the gut microbiota from the polyphenols ellagitannins
and ellagic acid, are discovered by the research group in humans almost 20 years ago. …

Scope Poly‐pharmacological therapy shapes the gut microbiota (GM) in metabolic syndrome
(MetS) patients. The effects of polyphenols in poly‐medicated MetS patients are unknown. …

Dietary (poly)phenols are extensively metabolized, limiting their anticancer activity. Exosomes
(EXOs) are extracellular vesicles that could protect polyphenols from metabolism. Our …

Environmental and genetic factors are associated with pandemic obesity since childhood.
However, the association of overweight-obesity with these factors, acting as a consortium, has …

Urolithin (Uro) production capacity and, consequently, at least partly, the health effects attributed
to ellagitannin and ellagic acid consumption vary among individuals. The reason is that …

Scope The stratification of individuals according to their gut microbiota metabotypes is crucial
to understand the polyphenols health effects as reported for isoflavones and ellagitannins. …